Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Sparrow Therapeutics second quarter 2025 earnings conference call. At this time, all participants are in the listen-only mode. Following the company's formal remark, we will open up the call for questions. Please be advised that this call is being recorded and a replay will be available. You can find the information in the replay and further information related to today's announcement on the Sparrow Therapeutics website at www.sperrotherapeutics.com. At this time, I would like to turn the call over to Shahi Biran, Senior Director, Investor Relations. Mr. Biran, please go ahead. Thank you, Operator, and thank you all for participating in today's conference call. This afternoon, Sparrow Therapeutics released financial results and provided a business update for the second quarter of 2025. The press release is available on the investor page of the Sparrow Therapeutics website. Before we begin, I would like to remind you that some of the information presented on this conference call contains forward-looking statements under the Private Securities Litigation Reform Act of 1995 as amended. These forward-looking statements are based on management's current expectations and beliefs and are subject to risks, uncertainties, and other factors that may cause actual results to differ materially from those indicated by such forward-looking statements. These risks uncertainties, and other factors are described in detail in Sphero-Therapeutics filings with the SEC, including in the risk factors set forth in the periodic report on Form 10-Q for the second quarter ended June 30, 2025, filed with the SEC today. Leading our call today will be Esther Rajavelu, our Chief Executive Officer and Chief Financial Officer. She will be joined by our Chief Operating O...